Alpine Immune Sciences' Autoimmune Disease Candidate ALPN-303 Shows Promise in Preclinical Studies

  • Alpine Immune Sciences Inc ALPN has presented the preclinical data from its ALPN-303 program at the European Alliance of Associations for Rheumatology (EULAR) European Congress of Rheumatology Virtual Meeting.
  • ALPN-303 inhibited the activity of the B cell cytokines APRIL and BAFF more potently than wild-type TACI-Fc counterparts, as well as an anti-BAFF antibody.
  • ALPN-303 exhibited favorable preliminary developability characteristics, including higher serum exposure, lower clinical doses, or longer dosing intervals compared to WT TACI-Fc therapeutics.
  • In a mouse model of lupus, ALPN-303 treatment significantly suppressed anti-double-stranded DNA antibody titers, inflammation in the kidneys (glomerulonephritis), and salivary glands (sialadenitis) while preserving renal function and improving survival.
  • ALPN-303 is a potential candidate for the treatment of multiple autoimmune and inflammatory diseases, focusing on B cell-related disorders.
  • The first-in-human study is expected to start in later 2021.
  • See the slide presentation here.
  • Related content: Benzinga's Full FDA Calendar.
  • Price Action: ALPN shares closed at $10.14 on Wednesday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsHealth CareFDAGeneralautoimmune diseasesBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!